Skip to main content

Peer Review reports

From: Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults

Original Submission
9 Mar 2023 Submitted Original manuscript
30 Apr 2023 Reviewed Reviewer Report - José Javier Morales-Núñez
30 Apr 2023 Reviewed Reviewer Report
17 May 2023 Author responded Author comments - Guoping Sheng
Resubmission - Version 2
17 May 2023 Submitted Manuscript version 2
Publishing
22 May 2023 Editorially accepted
27 Jun 2023 Article published 10.1186/s12879-023-08341-6

You can find further information about peer review here.

Back to article page